{"database": "openregs", "table": "documents", "is_view": false, "human_description_en": "where agency_id = \"FDA\" and docket_id = \"FDA-2005-N-0453\" sorted by posted_date descending", "rows": [["FDA-2005-N-0453-0055", "FDA", "FDA-2005-N-0453", "DSM Nutritional Products June 7 2019 Meeting Minutes", "Other", "Minutes", "2019-08-28T04:00:00Z", 2019, 8, "2019-08-28T04:00:00Z", null, "2019-08-28T18:40:49Z", null, 0, 0, "0900006483ed5517"], ["FDA-2005-N-0453-0054", "FDA", "FDA-2005-N-0453", "Letter from FDA CDER to DSM Nutritional Products LLC", "Other", "Letter(s)", "2019-06-05T04:00:00Z", 2019, 6, "2019-06-05T04:00:00Z", null, "2019-06-05T15:49:14Z", null, 0, 0, "0900006483ced582"], ["FDA-2005-N-0453-0053", "FDA", "FDA-2005-N-0453", "Request for Type C Meeting from DSM", "Other", "Request", "2019-05-01T04:00:00Z", 2019, 5, "2019-05-01T04:00:00Z", null, "2019-05-01T18:52:26Z", null, 0, 0, "0900006483c25323"], ["FDA-2005-N-0453-0052", "FDA", "FDA-2005-N-0453", "Request for Non Public Meeting from DSM Nutritional Products", "Other", "Request", "2019-01-29T05:00:00Z", 2019, 1, "2019-01-29T05:00:00Z", null, "2019-01-29T18:45:00Z", null, 0, 0, "0900006483a2238b"], ["FDA-2005-N-0453-0051", "FDA", "FDA-2005-N-0453", "MEMORANDUM OF MEETING MINUTES - BASF Bemotrizinol and Bisoctrizole October 12, 2017", "Other", "Memorandum", "2017-11-15T05:00:00Z", 2017, 11, "2017-11-15T05:00:00Z", null, "2017-11-15T17:48:04Z", null, 0, 0, "0900006482c7b23a"], ["FDA-2005-N-0453-0050", "FDA", "FDA-2005-N-0453", "Revision from BASF (Morgan, Lewis & Bockius LLP)", "Other", "Correction(s)", "2017-09-29T04:00:00Z", 2017, 9, "2017-09-29T04:00:00Z", null, "2017-09-29T20:24:09Z", null, 0, 0, "0900006482b8cb9f"], ["FDA-2005-N-0453-0049", "FDA", "FDA-2005-N-0453", "Meeting Granted Letter BASF August 28 2017 Meeting Request", "Other", "Memorandum", "2017-09-19T04:00:00Z", 2017, 9, "2017-09-19T04:00:00Z", null, "2017-09-19T18:12:14Z", null, 0, 0, "0900006482b4f4e1"], ["FDA-2005-N-0453-0048", "FDA", "FDA-2005-N-0453", "Meeting Materials from BASF (Morgan, Lewis & Bockius LLP)", "Other", "Meeting Exhibits", "2017-09-12T04:00:00Z", 2017, 9, "2017-09-12T04:00:00Z", null, "2017-09-29T20:24:44Z", null, 0, 0, "0900006482b2bf58"], ["FDA-2005-N-0453-0047", "FDA", "FDA-2005-N-0453", "Request for Meeting from BASF (Morgan, Lewis & Bockius LLP)", "Other", "Request", "2017-09-01T04:00:00Z", 2017, 9, "2017-09-01T04:00:00Z", null, "2017-09-01T18:56:18Z", null, 0, 0, "0900006482b03dc4"], ["FDA-2005-N-0453-0045", "FDA", "FDA-2005-N-0453", "Letter from BASF SE (Morgan, Lewis & Bockius LLP)", "Other", "Letter(s)", "2015-10-15T04:00:00Z", 2015, 10, "2015-10-15T04:00:00Z", null, "2015-10-15T14:41:58Z", null, 0, 0, "0900006481ccce50"], ["FDA-2005-N-0453-0046", "FDA", "FDA-2005-N-0453", "Advice Letter from FDA CDER to Morgan, Lewis & Bockius LLP", "Other", "Letter(s)", "2015-10-15T04:00:00Z", 2015, 10, "2015-10-15T04:00:00Z", null, "2015-10-15T14:42:13Z", null, 0, 0, "0900006481ccce52"], ["FDA-2005-N-0453-0042", "FDA", "FDA-2005-N-0453", "Memorandum of Meeting Minutes between FDA CDER and BASF regarding Octyl Triazone and Bemotrizinol March 19, 2015", "Other", "Memorandum", "2015-06-15T04:00:00Z", 2015, 6, "2015-06-15T04:00:00Z", null, "2015-06-15T17:13:28Z", null, 0, 0, "0900006481b37e78"], ["FDA-2005-N-0453-0043", "FDA", "FDA-2005-N-0453", "Memorandum of Meeting Minutes between FDA CDER and BASF Corporation regarding bisoctrizole March 20, 2015", "Other", "Memorandum", "2015-06-15T04:00:00Z", 2015, 6, "2015-06-15T04:00:00Z", null, "2015-06-15T17:13:48Z", null, 0, 0, "0900006481b37e79"], ["FDA-2005-N-0453-0041", "FDA", "FDA-2005-N-0453", "Letter from FDA/CDER to Morgan, Lewis & Bockius, LLP (BASF SE) Granting Meeting Request Regarding GRASE Status of Octyl Triazone and Bemotrizinol", "Other", "Letter(s)", "2015-03-09T04:00:00Z", 2015, 3, "2015-03-09T04:00:00Z", null, "2015-03-09T13:44:40Z", null, 0, 0, "0900006481a33de1"], ["FDA-2005-N-0453-0040", "FDA", "FDA-2005-N-0453", "Letter from FDA/CDER to Morgan, Lewis & Bockius, LLP (BASF SE) Granting Meeting Request Regarding GRASE Status of Bisoctrizole", "Other", "Letter(s)", "2015-03-09T04:00:00Z", 2015, 3, "2015-03-09T04:00:00Z", null, "2015-03-09T13:40:04Z", null, 0, 0, "0900006481a33ddd"], ["FDA-2005-N-0453-0036", "FDA", "FDA-2005-N-0453", "Sunscreen Feedback Letters; Notice of Availability Under the Sunscreen\nInnovation Act", "Notice", "Request for Comments", "2015-01-07T05:00:00Z", 2015, 1, "2015-01-07T05:00:00Z", "2015-02-24T04:59:59Z", "2015-02-24T03:08:50Z", "2015-00002", 0, 0, "09000064819a9732"], ["FDA-2005-N-0453-0035", "FDA", "FDA-2005-N-0453", "Determination and Feedback Letter from FDA/CDER to Ciba Specialty Chemicals Corporation (Ciba) (Morgan, Lewis & Bockius LLP) re Time and Extent Application (TEA) Bemotrizinol for use in Over-the-Counter (OTC) Sunscreen", "Other", "Letter(s)", "2014-11-14T05:00:00Z", 2014, 11, "2014-11-14T05:00:00Z", null, "2014-11-14T20:28:13Z", null, 0, 0, "090000648192f333"], ["FDA-2005-N-0453-0034", "FDA", "FDA-2005-N-0453", "Initial Determination and Feedback Letter from FDA/CDER to Ciba Specialty Chemicals Corporation (Ciba) (Morgan, Lewis & Bockius LLP) re Time and Extent Application (TEA) Bemotrizinol  for use in Over-the-Counter (OTC) Sunscreens", "Other", null, "2014-11-13T00:00:00Z", 2014, 11, null, null, "2014-11-14T16:27:35Z", null, 0, 1, "090000648192d191"], ["FDA-2005-N-0453-0028", "FDA", "FDA-2005-N-0453", "Tab. III A.12 Lifetime Dermal Carcinogenicity Study in Rats Volume 8 of 12 re Supplement from Ciba Specialty Chemicals Corporation", "Supporting & Related Material", "Background Material", "2014-11-10T05:00:00Z", 2014, 11, null, null, "2014-11-10T16:28:36Z", null, 0, 0, "0900006481902a13"], ["FDA-2005-N-0453-0022", "FDA", "FDA-2005-N-0453", "Tab. III A.12 Lifetime Dermal Carcinogenicity Study in Rats Volume 2 of 12 re Supplement from Ciba Specialty Chemicals Corporation", "Supporting & Related Material", "Background Material", "2014-11-10T05:00:00Z", 2014, 11, null, null, "2014-11-10T16:20:46Z", null, 0, 0, "09000064819029b7"], ["FDA-2005-N-0453-0025", "FDA", "FDA-2005-N-0453", "Tab. III A.12 Lifetime Dermal Carcinogenicity Study in Rats Volume 5 of 12 re Supplement from Ciba Specialty Chemicals Corporation", "Supporting & Related Material", "Background Material", "2014-11-10T05:00:00Z", 2014, 11, null, null, "2014-11-10T16:22:33Z", null, 0, 0, "09000064819029bf"], ["FDA-2005-N-0453-0031", "FDA", "FDA-2005-N-0453", "Tab. III A.12 Lifetime Dermal Carcinogenicity Study in Rats Volume 11 of 12 re Supplement from Ciba Specialty Chemicals Corporation", "Supporting & Related Material", "Background Material", "2014-11-10T05:00:00Z", 2014, 11, null, null, "2014-11-10T16:30:27Z", null, 0, 0, "0900006481902a27"], ["FDA-2005-N-0453-0021", "FDA", "FDA-2005-N-0453", "Tab. III A.12 Lifetime Dermal Carcinogenicity Study in Rats Volume 1 of 12 re Supplement from Ciba Specialty Chemicals Corporation", "Supporting & Related Material", "Background Material", "2014-11-10T05:00:00Z", 2014, 11, null, null, "2014-11-10T16:19:48Z", null, 0, 0, "090000648190293f"], ["FDA-2005-N-0453-0024", "FDA", "FDA-2005-N-0453", "Tab. III A.12 Lifetime Dermal Carcinogenicity Study in Rats Volume 4 of 12 re Supplement from Ciba Specialty Chemicals Corporation", "Supporting & Related Material", "Background Material", "2014-11-10T05:00:00Z", 2014, 11, null, null, "2014-11-10T16:22:05Z", null, 0, 0, "09000064819029bb"], ["FDA-2005-N-0453-0027", "FDA", "FDA-2005-N-0453", "Tab. III A.12 Lifetime Dermal Carcinogenicity Study in Rats Volume 7 of 12 re Supplement from Ciba Specialty Chemicals Corporation", "Supporting & Related Material", "Background Material", "2014-11-10T05:00:00Z", 2014, 11, null, null, "2014-11-10T16:27:57Z", null, 0, 0, "0900006481902a10"], ["FDA-2005-N-0453-0033", "FDA", "FDA-2005-N-0453", "Bemotrizinol Dermal Carcinogenicity Summary re Supplement from Ciba Specialty Chemicals", "Supporting & Related Material", "Background Material", "2014-11-10T05:00:00Z", 2014, 11, null, null, "2014-11-10T16:34:50Z", null, 0, 0, "0900006481902a2b"], ["FDA-2005-N-0453-0026", "FDA", "FDA-2005-N-0453", "Tab. III A.12 Lifetime Dermal Carcinogenicity Study in Rats Volume 6 of 12 re Supplement from Ciba Specialty Chemicals Corporation", "Supporting & Related Material", "Background Material", "2014-11-10T05:00:00Z", 2014, 11, null, null, "2014-11-10T16:27:16Z", null, 0, 0, "09000064819029e2"], ["FDA-2005-N-0453-0030", "FDA", "FDA-2005-N-0453", "Tab. III A.12 Lifetime Dermal Carcinogenicity Study in Rats Volume 10 of 12 re Supplement from Ciba Specialty Chemicals Corporation", "Supporting & Related Material", "Background Material", "2014-11-10T05:00:00Z", 2014, 11, null, null, "2014-11-10T16:29:54Z", null, 0, 0, "0900006481902a25"], ["FDA-2005-N-0453-0023", "FDA", "FDA-2005-N-0453", "Tab. III A.12 Lifetime Dermal Carcinogenicity Study in Rats Volume 3 of 12 re Supplement from Ciba Specialty Chemicals Corporation", "Supporting & Related Material", "Background Material", "2014-11-10T05:00:00Z", 2014, 11, null, null, "2014-11-10T16:21:25Z", null, 0, 0, "09000064819029b9"], ["FDA-2005-N-0453-0032", "FDA", "FDA-2005-N-0453", "Tab. III A.12 Lifetime Dermal Carcinogenicity Study in Rats Volume 12 of 12 re Supplement from Ciba Specialty Chemicals Corporation", "Supporting & Related Material", "Background Material", "2014-11-10T05:00:00Z", 2014, 11, null, null, "2014-11-10T16:31:54Z", null, 0, 0, "0900006481902a29"], ["FDA-2005-N-0453-0029", "FDA", "FDA-2005-N-0453", "Tab. III A.12 Lifetime Dermal Carcinogenicity Study in Rats Volume 9 of 12 re Supplement from Ciba Specialty Chemicals Corporation", "Supporting & Related Material", "Background Material", "2014-11-10T05:00:00Z", 2014, 11, null, null, "2014-11-10T16:29:14Z", null, 0, 0, "0900006481902a17"], ["FDA-2005-N-0453-0020", "FDA", "FDA-2005-N-0453", "Initial Determination and Feedback Letter from FDA/CDER to Ciba Specialty Chemicals Corporation (Ciba) (Morgan, Lewis & Bockius LLP) re Time and Extent Application (TEA) Bisoctrizole for use in Over-the-Counter (OTC) Sunscreens", "Other", "Letter(s)", "2014-09-03T04:00:00Z", 2014, 9, "2014-09-03T04:00:00Z", null, "2014-09-03T21:02:03Z", null, 0, 0, "090000648185a6e7"], ["FDA-2005-N-0453-0019", "FDA", "FDA-2005-N-0453", "Ciba Specialty Chemicals Corporation Correspondence with FDA Center for Drug Evaluation & Research - Electronic Letter re FDA-2005-N-0453-0002 and FDA-2005-N-0453-0003", "Other", "Electronic Letter", "2014-09-03T04:00:00Z", 2014, 9, "2014-09-03T04:00:00Z", null, "2014-09-03T20:44:01Z", null, 0, 0, "09000064812be491"], ["FDA-2005-N-0453-0017", "FDA", "FDA-2005-N-0453", "Electronic Correspondence From Ciba to FDA re Confidential Information in Bisoctrizole and Bemotrizinol TEAs FDA-2005-N-0453-0001- Background", "Supporting & Related Material", "Background Material", "2013-05-07T04:00:00Z", 2013, 5, null, null, "2013-05-07T21:36:09Z", null, 0, 0, "09000064804507d4"], ["FDA-2005-N-0453-0018", "FDA", "FDA-2005-N-0453", "Electronic Correspondence From Ciba to FDA re Confidential Information in Bisoctrizole and Bemotrizinol TEAs FDA-2005-N-0453-0001 - Background", "Supporting & Related Material", "Background Material", "2013-05-07T04:00:00Z", 2013, 5, null, null, "2013-05-07T21:36:43Z", null, 0, 0, "09000064804507d9"], ["FDA-2005-N-0453-0016", "FDA", "FDA-2005-N-0453", "Skin Cancer Foundation to the Food and Drug Administration - Letter", "Other", "Letter(s)", "2008-08-19T04:00:00Z", 2008, 8, "2008-08-19T04:00:00Z", null, "2019-07-05T19:37:20Z", null, 0, 0, "090000648063d6c7"], ["FDA-2005-N-0453-0004", "FDA", "FDA-2005-N-0453", "Time and Extent Application (TEA) Review for Bemotrizinol [FDA-2005-N-0453-0001] - Background", "Supporting & Related Material", "Background Material", "2008-06-13T04:00:00Z", 2008, 6, null, null, "2013-05-02T17:00:12Z", null, 0, 0, "09000064804507cf"], ["FDA-2005-N-0453-0005", "FDA", "FDA-2005-N-0453", "Time and Extent Application (TEA) Review for Bisoctrizole [FDA-2005-N-0453-0001] - Background", "Supporting & Related Material", "Background Material", "2008-06-13T04:00:00Z", 2008, 6, null, null, "2013-05-02T17:03:52Z", null, 0, 0, "09000064804507d0"], ["FDA-2005-N-0453-0010", "FDA", "FDA-2005-N-0453", "FDA Center for Drug Evaluation and Reseach (OTC) to Ciba Specialty Chemical Corporation Letter dated 10/31/2005 [FDA-2005-N-0453-0001] - Background", "Supporting & Related Material", "BKG-Background Material", "2008-06-13T04:00:00Z", 2008, 6, null, null, "2013-05-02T17:12:19Z", null, 0, 0, "09000064804507d8"], ["FDA-2005-N-0453-0003", "FDA", "FDA-2005-N-0453", "Ciba Specialty Chemicals Corporation - [Bemotrizinol] - Supplement", "Other", "Supplement (SUP)", "2008-06-13T04:00:00Z", 2008, 6, "2008-06-13T04:00:00Z", null, "2013-05-07T21:31:57Z", null, 0, 0, "09000064804507e3"], ["FDA-2005-N-0453-0013", "FDA", "FDA-2005-N-0453", "Time and Extend Application Bemotrizinol [Product Labeling] [FDA-2005-N-0453-0001] - Background", "Supporting & Related Material", "Background Material", "2008-06-13T04:00:00Z", 2008, 6, null, null, "2013-05-02T17:31:03Z", null, 0, 0, "09000064804507dc"], ["FDA-2005-N-0453-0012", "FDA", "FDA-2005-N-0453", "Time and Extend Application Bemotrizinol - [Appendices] [FDA-2005-N-0453-0001] - Background", "Supporting & Related Material", "Background Material", "2008-06-13T04:00:00Z", 2008, 6, null, null, "2013-05-02T17:29:25Z", null, 0, 0, "09000064804507db"], ["FDA-2005-N-0453-0009", "FDA", "FDA-2005-N-0453", "Time and Extend Application Bisoctrizole [Product Labeling] [FDA-2005-N-0453-0001] - Background", "Supporting & Related Material", "Background Material", "2008-06-13T04:00:00Z", 2008, 6, null, null, "2013-05-02T17:10:59Z", null, 0, 0, "09000064804507d7"], ["FDA-2005-N-0453-0011", "FDA", "FDA-2005-N-0453", "Time and Extend Application Bemotrizinol - [Prepared to support the Inclusion of Bemotrizinol  into FDA\u2019s Monograph for Sunscreen Drug Products] [FDA-2005-N-0453-0001] - Background", "Supporting & Related Material", "Background Material", "2008-06-13T04:00:00Z", 2008, 6, null, null, "2013-05-02T17:15:05Z", null, 0, 0, "09000064804507da"], ["FDA-2005-N-0453-0007", "FDA", "FDA-2005-N-0453", "Time and Extend Application Bisoctrizole - [Prepared to support the Inclusion of Bisoctrizole into FDA\u2019s Monograph for Sunscreen Drug Products]  [FDA-2005-N-0453-0001] - Background", "Supporting & Related Material", "Background Material", "2008-06-13T04:00:00Z", 2008, 6, null, null, "2013-05-02T17:06:46Z", null, 0, 0, "09000064804507d5"], ["FDA-2005-N-0453-0008", "FDA", "FDA-2005-N-0453", "Time and Extend Application Bisoctrizole - [Appendices] [FDA-2005-N-0453-0001] - Background", "Supporting & Related Material", "Background Material", "2008-06-13T04:00:00Z", 2008, 6, null, null, "2013-05-02T17:09:09Z", null, 0, 0, "09000064804507d6"], ["FDA-2005-N-0453-0002", "FDA", "FDA-2005-N-0453", "Ciba Specialty Chemicals Corporation re Bisoctrizole - Supplement", "Other", "Supplement (SUP)", "2008-06-13T04:00:00Z", 2008, 6, "2008-06-13T04:00:00Z", null, "2013-05-07T21:31:02Z", null, 0, 0, "09000064804507e2"], ["FDA-2005-N-0453-0006", "FDA", "FDA-2005-N-0453", "FDA Center for Drug Evaluation and Reseach (OTC) to Ciba Specialty Chemical Corporation Letter dated 10/31/2005 [FDA-2005-N-0453-0001] - Background", "Supporting & Related Material", "Background Material", "2008-06-13T04:00:00Z", 2008, 6, null, null, "2013-05-02T17:03:01Z", null, 0, 0, "09000064804507d3"], ["FDA-2005-N-0453-0001", "FDA", "FDA-2005-N-0453", "Over-the-Counter Drug Products; Safety and Efficacy Review; Additional Sunscreen Ingredients", "Notice", "NRD-Notice of Requesting Data, Info, & Views", "2005-12-02T05:00:00Z", 2005, 12, "2005-12-05T05:00:00Z", "2006-03-07T04:59:59Z", "2009-12-30T19:54:55Z", null, 0, 0, "09000064804507c9"]], "truncated": false, "filtered_table_rows_count": 49, "expanded_columns": [], "expandable_columns": [[{"column": "docket_id", "other_table": "dockets", "other_column": "id"}, "title"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "units": {}, "query": {"sql": "select id, agency_id, docket_id, title, document_type, subtype, posted_date, posted_year, posted_month, comment_start_date, comment_end_date, last_modified, fr_doc_num, open_for_comment, withdrawn, object_id from documents where \"agency_id\" = :p0 and \"docket_id\" = :p1 order by posted_date desc limit 101", "params": {"p0": "FDA", "p1": "FDA-2005-N-0453"}}, "facet_results": {"agency_id": {"name": "agency_id", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?agency_id=FDA&docket_id=FDA-2005-N-0453", "results": [{"value": "FDA", "label": "FDA", "count": 49, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2005-N-0453", "selected": true}], "truncated": false}, "document_type": {"name": "document_type", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?agency_id=FDA&docket_id=FDA-2005-N-0453", "results": [{"value": "Supporting & Related Material", "label": "Supporting & Related Material", "count": 25, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2005-N-0453&document_type=Supporting+%26+Related+Material", "selected": false}, {"value": "Other", "label": "Other", "count": 22, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2005-N-0453&document_type=Other", "selected": false}, {"value": "Notice", "label": "Notice", "count": 2, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2005-N-0453&document_type=Notice", "selected": false}], "truncated": false}, "posted_year": {"name": "posted_year", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?agency_id=FDA&docket_id=FDA-2005-N-0453", "results": [{"value": 2014, "label": 2014, "count": 17, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2005-N-0453&posted_year=2014", "selected": false}, {"value": 2008, "label": 2008, "count": 13, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2005-N-0453&posted_year=2008", "selected": false}, {"value": 2015, "label": 2015, "count": 7, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2005-N-0453&posted_year=2015", "selected": false}, {"value": 2017, "label": 2017, "count": 5, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2005-N-0453&posted_year=2017", "selected": false}, {"value": 2019, "label": 2019, "count": 4, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2005-N-0453&posted_year=2019", "selected": false}, {"value": 2013, "label": 2013, "count": 2, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2005-N-0453&posted_year=2013", "selected": false}, {"value": 2005, "label": 2005, "count": 1, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2005-N-0453&posted_year=2005", "selected": false}], "truncated": false}}, "suggested_facets": [{"name": "subtype", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2005-N-0453&_facet=subtype"}, {"name": "posted_date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2005-N-0453&_facet=posted_date"}, {"name": "posted_month", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2005-N-0453&_facet=posted_month"}, {"name": "comment_start_date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2005-N-0453&_facet=comment_start_date"}, {"name": "withdrawn", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2005-N-0453&_facet=withdrawn"}, {"name": "posted_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2005-N-0453&_facet_date=posted_date"}, {"name": "comment_start_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2005-N-0453&_facet_date=comment_start_date"}, {"name": "comment_end_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2005-N-0453&_facet_date=comment_end_date"}, {"name": "last_modified", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2005-N-0453&_facet_date=last_modified"}], "next": null, "next_url": null, "private": false, "allow_execute_sql": true, "query_ms": 1478.7992588244379, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}